Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jun;65(6):898–902. doi: 10.1038/bjc.1992.188

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

H J Guchelaar 1, H J Hoekstra 1, E G de Vries 1, D R Uges 1, J W Oosterhuis 1, H Schraffordt Koops 1
PMCID: PMC1977776  PMID: 1319729

Full text

PDF
898

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Peng Y. M., Chen H. S., Moon T. E., Cetas T. C., Hoeschele J. D. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst. 1980 Aug;65(2):455–461. [PubMed] [Google Scholar]
  2. Bielack S. S., Erttmann R., Looft G., Purfürst C., Delling G., Winkler K., Landbeck G. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. Cancer Chemother Pharmacol. 1989;24(6):376–380. doi: 10.1007/BF00257446. [DOI] [PubMed] [Google Scholar]
  3. Bues-Charbit M., Gentet J. C., Bernard J. L., Breant V., Cano J. P., Raybaud C. Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1649–1652. doi: 10.1016/0277-5379(87)90444-5. [DOI] [PubMed] [Google Scholar]
  4. CREECH O., Jr, KREMENTZ E. T., RYAN R. F., WINBLAD J. N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958 Oct;148(4):616–632. doi: 10.1097/00000658-195810000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cavaliere R., Ciocatto E. C., Giovanella B. C., Heidelberger C., Johnson R. O., Margottini M., Mondovi B., Moricca G., Rossi-Fanelli A. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967 Sep;20(9):1351–1381. doi: 10.1002/1097-0142(196709)20:9<1351::aid-cncr2820200902>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  6. Dominici C., Petrucci F., Caroli S., Alimonti A., Clerico A., Castello M. A. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989 Jan;7(1):100–107. doi: 10.1200/JCO.1989.7.1.100. [DOI] [PubMed] [Google Scholar]
  7. Fontijne W. P., Mook P. H., Koops H. S., Oldhoff J., Wildevuur C. R. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer. 1985 Apr 1;55(7):1455–1461. doi: 10.1002/1097-0142(19850401)55:7<1455::aid-cncr2820550706>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  8. Forastiere A. A., Belliveau J. F., Goren M. P., Vogel W. C., Posner M. R., O'Leary G. P., Jr Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res. 1988 Jul 1;48(13):3869–3874. [PubMed] [Google Scholar]
  9. Giovanella B. C., Morgan A. C., Stehlin J. S., Williams L. J. Selective lethal effect of supranormal temperatures on mouse sarcoma cells. Cancer Res. 1973 Nov;33(11):2568–2578. [PubMed] [Google Scholar]
  10. Giovanella B. C., Stehlin J. S., Jr, Morgan A. C. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 1976 Nov;36(11 Pt 1):3944–3950. [PubMed] [Google Scholar]
  11. Gormley P. E., Bull J. M., LeRoy A. F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979 Mar;25(3):351–357. doi: 10.1002/cpt1979253351. [DOI] [PubMed] [Google Scholar]
  12. Gullo J. J., Litterst C. L., Maguire P. J., Sikic B. I., Hoth D. F., Woolley P. V. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980;5(1):21–26. doi: 10.1007/BF00578558. [DOI] [PubMed] [Google Scholar]
  13. Hahn G. M. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979 Jun;39(6 Pt 2):2264–2268. [PubMed] [Google Scholar]
  14. Herman T. S., Teicher B. A., Chan V., Collins L. S., Abrams M. J. Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):443–449. doi: 10.1016/0360-3016(89)90340-4. [DOI] [PubMed] [Google Scholar]
  15. Herman T. S. Temperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res. 1983 Feb;43(2):517–520. [PubMed] [Google Scholar]
  16. Hoekstra H. J., Schraffordt Koops H., Molenaar W. M., Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer. 1987 Oct 15;60(8):1703–1707. doi: 10.1002/1097-0142(19871015)60:8<1703::aid-cncr2820600802>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  17. Kase K., Hahn G. M. Differential heat response of normal and transformed human cells in tissue culture. Nature. 1975 May 15;255(5505):228–230. doi: 10.1038/255228a0. [DOI] [PubMed] [Google Scholar]
  18. LeRoy A. F., Lutz R. J., Dedrick R. L., Litterst C. L., Guarino A. M. Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu. Cancer Treat Rep. 1979 Jan;63(1):59–71. [PubMed] [Google Scholar]
  19. Lejeune F. J., Ghanem G. E. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res. 1987 Jan 15;47(2):639–643. [PubMed] [Google Scholar]
  20. Meyn R. E., Corry P. M., Fletcher S. E., Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 1980 Apr;40(4):1136–1139. [PubMed] [Google Scholar]
  21. Pommier R. F., Moseley H. S., Cohen J., Huang C. S., Townsend R., Fletcher W. S. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg. 1988 May;155(5):667–671. doi: 10.1016/s0002-9610(88)80140-5. [DOI] [PubMed] [Google Scholar]
  22. Riviere J. E., Page R. L., Dewhirst M. W., Tyczkowska K., Thrall D. E. Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. Int J Hyperthermia. 1986 Oct-Dec;2(4):351–358. doi: 10.3109/02656738609004965. [DOI] [PubMed] [Google Scholar]
  23. Roseman J. M. Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. J Surg Oncol. 1987 Jul;35(3):170–172. doi: 10.1002/jso.2930350306. [DOI] [PubMed] [Google Scholar]
  24. Roseman J. M., Tench D., Bryant L. R. The safe use of cisplatin in hyperthermic isolated limb perfusion systems. Cancer. 1985 Aug 15;56(4):742–744. doi: 10.1002/1097-0142(19850815)56:4<742::aid-cncr2820560407>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  25. Song C. W., Kang M. S., Rhee J. G., Levitt S. H. The effect of hyperthermia on vascular function, pH, and cell survival. Radiology. 1980 Dec;137(3):795–803. doi: 10.1148/radiology.137.3.7444064. [DOI] [PubMed] [Google Scholar]
  26. Stehlin J. S., Jr Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969 Aug;129(2):305–308. [PubMed] [Google Scholar]
  27. Terheggen P. M., Dijkman R., Begg A. C., Dubbelman R., Floot B. G., Hart A. A., den Engelse L. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res. 1988 Oct 1;48(19):5597–5603. [PubMed] [Google Scholar]
  28. Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., Pinedo H. M. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069–1074. doi: 10.1016/0277-5379(82)90085-2. [DOI] [PubMed] [Google Scholar]
  29. Wallner K. E., DeGregorio M. W., Li G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 1986 Dec;46(12 Pt 1):6242–6245. [PubMed] [Google Scholar]
  30. Wieberdink J., Benckhuysen C., Braat R. P., van Slooten E. A., Olthuis G. A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982 Oct;18(10):905–910. doi: 10.1016/0277-5379(82)90235-8. [DOI] [PubMed] [Google Scholar]
  31. van Os J., Schraffordt Koops H., Oldhoff J. Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Cancer. 1985 Feb 15;55(4):698–701. doi: 10.1002/1097-0142(19850215)55:4<698::aid-cncr2820550404>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  32. van Os J., Schraffordt Koops H., Oldhoff J., Wildevuur C. R. Hyperthermic regional perfusion using membrane- instead of bubble-oxygenators. An experimental and clinical study. J Cardiovasc Surg (Torino) 1989 Jul-Aug;30(4):523–532. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES